TAK-653

weak data

Also seen as: osavampator, NBI-1065845, NBI-845, TAK653

The Dose Guy’s verdict

Sep 1, 2026
3 sources

TAK-653 is the most interesting AMPA modulator on the shelf right now, and it is not ready. A major pharma company built it for depression, the early human data shows real cortical engagement, and the preclinical seizure margin is the widest I have seen in this class: 419-fold on plasma Cmax, 1017-fold on exposure. But no efficacy trial has reported, there is no approved indication, and the compound is not broadly available. This is a watch, not a run. If the AMPA mechanism is what draws you and you want something you can actually source today, sunifiram and unifiram are the community options, with the caveat that neither has any human data at all.

Would I take it?Caution, promising but unfinished.

What it is

An oral AMPA receptor positive allosteric modulator, meaning it makes the brain’s main excitatory receptors respond more strongly to their natural signal without firing them on its own. The AMPA system sits underneath learning, memory, and mood, and TAK-653 potentiates it with a wide safety margin against the seizure risk that killed earlier ampakines. It also raises BDNF and activates mTOR signaling in neurons, the same downstream machinery that ketamine’s antidepressant effect runs through, which is why the depression angle is the primary development bet.

On the nootropic shelf it shares AMPA territory with sunifiram and unifiram, but TAK-653 is the only one of the group with human data from controlled studies.

What the research shows

Real human pharmacodynamic data in healthy volunteers, solid preclinical pharmacology, no published efficacy trial for the target indication yet.

In 24 healthy volunteers, TAK-653 at 6 mg improved adaptive tracking by 1.68 percentage points versus placebo (p=0.02). A small cognitive signal, but a real one in a real person.Transl Psychiatry 2022 · crossover · n=24

In a separate crossover study of 24 healthy volunteers, TAK-653 increased motor-evoked potential amplitude after transcranial magnetic stimulation, confirming the drug reaches the cortex and changes excitability.Transl Psychiatry 2021 · crossover · n=24

After two weeks of TAK-653, chronically stressed monkeys showed greater food motivation, more activity, less huddling, and moved toward upper areas of their enclosure. Behavioral recovery in a depression model, not a dish.Biomedicines 2025 · monkey model

No published efficacy trial for depression or any other clinical endpoint. The human data so far is mechanism-of-action and tolerability, not outcomes.as of Aug 2026

Realistic protocols

TAK-653 is in active pharmaceutical development and is not sold as a research chemical. The human studies used 0.5 mg and 6 mg oral doses, and the 6 mg dose is where the cognitive and cortical signals showed up. If you source it through gray-market channels, which some people do, start at the low end of what the trials tested, keep the run short, and understand that you are ahead of the safety data, not behind it. There is no community protocol to draw from because the community barely runs this compound yet. The drug-interaction study found it does not inhibit or induce CYP3A, which means it is unlikely to interfere with most other drugs, one genuinely useful piece of the picture. I am not building a protocol table out of two PD studies in healthy volunteers.

Side effects

Side-effect data comes from healthy-volunteer studies and animal work:

monitorAMPA potentiators carry a theoretical seizure risk. In rats, TAK-653 showed a 419-fold Cmax margin and a 1017-fold exposure margin against convulsion, which reads as a wide buffer, but the class history earns respect.

unknownNo long-term human safety data. The compound has been in people for single doses and short courses only. The published data does not break out individual adverse events.

Where to buy

No live listings from tracked vendors right now.